These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29767854)

  • 1. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.
    Tanaka M; Komaba H; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):242-245. PubMed ID: 29767854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of secondary hyperparathyroidism: how and why?
    Komaba H; Kakuta T; Fukagawa M
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):37-45. PubMed ID: 28044233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
    Mizobuchi M; Ogata H; Koiwa F
    Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.
    Cozzolino M; Gallieni M; Pasho S; Fallabrino G; Ciceri P; Volpi EM; Olivi L; Brancaccio D
    Drugs Aging; 2009; 26(6):457-68. PubMed ID: 19591520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy.
    Tsai SH; Kan WC; Jhen RN; Chang YM; Kao JL; Lai HY; Liou HH; Shiao CC
    Clin Med (Lond); 2024 Sep; 24(5):100238. PubMed ID: 39208984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.
    Jean G; Vanel T; Terrat JC; Chazot C
    Hemodial Int; 2010 Oct; 14(4):486-91. PubMed ID: 20955282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
    Jean G; Souberbielle JC; Chazot C
    Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
    Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term use of cinacalcet in children on regular hemodialysis.
    Youssef D
    Arab J Nephrol Transplant; 2012 Jan; 5(1):51-3. PubMed ID: 22283867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysphoria induced in dialysis providers by secondary hyperparathyroidism.
    Soomro IH; Goldfarb DS
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):9-11. PubMed ID: 25516914
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary Hyperparathyroidism in a Patient with CKD.
    Hyder R; Sprague SM
    Clin J Am Soc Nephrol; 2020 Jul; 15(7):1041-1043. PubMed ID: 32461217
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging drugs for secondary hyperparathyroidism.
    Cozzolino M; Tomlinson J; Walsh L; Bellasi A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.